- Quotes
- Dashboard
- Chart
- Historical Prices
- Options
- News & PR
- News
- Market Currents
- Press Releases
- Coverage
- Cramer
- Top Analysts
- Business Intelligence
- Transcripts
- Events
- Key Developments
- Earnings
- History & Projected
- Consensus
- Peer Earnings
- Filings
- SEC Filings
- Annual Report
- Financials
- Income Statement
- Balance Sheet
- Cash Flow
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
VICL Market Currents
more »
-
May 2 Vical (VICL): Q1 EPS of $0.00 beats by $0.07. Revenue of $11.5M (+1816% Y/Y) beats by $9M. (PR)
Comment![Earnings, Healthcare]
VICL in Focus
more »
VICL Related Articles
more »
VICL News
more »
-
at MarketWatch.com (Jan 6, 2012)
-
at CNBC.com (Dec 29, 2011)
-
at MarketWatch.com (Jul 15, 2011)
-
at MarketWatch.com (Jul 14, 2011)
-
at MarketWatch.com (Feb 14, 2011)
VICL Press Releases and Filings
more »
-
GlobeNewswire (Tue, 6:30AM)
-
GlobeNewswire (May 16, 2012)
-
GlobeNewswire (May 8, 2012)
-
GlobeNewswire (May 2, 2012)
-
GlobeNewswire (Apr 25, 2012)
VICL Latest Transcript
more »
VICL Cramer
more »
Currently, there are no Cramer articles on VICL.
VICL Instablog posts
more »
VICL vs. ETF Alternatives
Company Description
We research and develop biopharmaceutical products based on our patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. We believe the following areas of research offer the greatest potential for near-term commercialization for us and our... More
